Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

CD34 is crucial for skin tumor development in mice.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

Scalp biopsies are crucial for diagnosing hair loss causes in cutaneous lymphoma patients.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

M-CSF-stimulated myeloid cells can cause alopecia areata in mice.

The new Hairless R/J mice model improves imaging for tumor monitoring and cancer therapy evaluation.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Cancer-associated fibroblasts promote tumor growth in skin cancer.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Calretinin can help identify certain skin structures and tumors.

Cells from a skin condition can create new hair follicles and similar growths in mice, and a specific treatment can reduce these effects.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Long-standing benign tumors can become cancerous, especially in people with weakened immune systems.

HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.

Hair follicles help skin immune recovery after UVB exposure.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Thymus-derived Tregs, not peripherally-derived Tregs, primarily regulate type 1 diabetes in the NOD mouse model.

CD200- cells in hair follicles have a higher ability to regenerate hair.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Talquetamab may cause hair loss and skin issues.

Basal cell carcinomas may use IDO to protect themselves from the immune system.

The system allows precise control of gene expression in mouse skin, useful for studying skin biology.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

BST2 protein and certain T cells increase in early alopecia areata.

The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.

Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.